Labcorp's earnings call highlighted strong revenue growth, strategic acquisitions, and innovation in testing capabilities, driven by Diagnostics and Central Laboratories success. However, challenges such as lower-than-expected Early Development revenue and potential impacts from PAMA legislation were noted.

Company Guidance

During the Q3 2025 earnings call for Labcorp Holdings, the company provided guidance reflecting strong financial performance and strategic progress. Revenue for the quarter increased to $3.6 billion, marking a 9% growth compared to the previous year, with adjusted EPS growing by 19%. The Diagnostics segment saw revenue growth of 8.5%, driven by a 6% organic growth, and a margin improvement of 110 basis points. The Biopharma Laboratory Services (BLS) segment reported an 8% revenue increase, with Central Laboratories showing a robust 10% growth. However, the Early Development segment faced challenges, leading to plans for site consolidation and divestment impacting approximately $50 million in annual revenue. The company narrowed its 2025 enterprise revenue growth guidance to a range of 7.4% to 8%, with adjusted EPS guidance of $16.15 to $16.50, implying a 12% growth rate at the midpoint. Free cash flow guidance was raised to a range of $1.165 billion to $1.285 billion. Labcorp also emphasized its focus on expanding in high-growth therapeutic areas and leveraging technology and AI to enhance operational efficiency and customer experience.

Strong Revenue Growth and Margin Improvement

Labcorp reported an enterprise revenue increase to $3.6 billion, representing 9% growth compared to last year. Margin for the quarter improved by 100 basis points, driven by Diagnostics, and adjusted EPS grew by 19%.

Diagnostics and Central Laboratories Success

Diagnostics revenue increased by 8.5%, with strong organic growth of 6%. Central Laboratories growth was strong at 10% or 7% constant currency, which offset softness in Early Development.

Strategic Acquisitions and Partnerships

Labcorp signed agreements to acquire select clinical laboratory assets, such as Empire City Laboratories and Laboratory Alliance of Central New York, while completing the acquisition of oncology and clinical testing assets from BioReference Health.

Innovation in Testing Capabilities

Labcorp introduced several innovative testing capabilities, including expanded oncology and genetic testing, and is planning to offer the only FDA-cleared blood test to rule out Alzheimer's-related amyloid pathology in the primary care setting.

Consumer Business Growth

Labcorp launched several consumer-initiated tests through Labcorp OnDemand, including tests for lead exposure, ApoB for heart health, and a panel for healthy aging.

Investment in Technology and AI

Labcorp launched Labcorp Test Finder, a generative AI tool, and is investing in digital and AI capabilities to improve pathology, cytology, and microbiology.

Labcorp Holdings (LH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2026	2025 (Q4)	3.94 / -	3.45	―	―	―
Oct 28, 2025	2025 (Q3)	4.13 / 4.18	3.5	19.43% (+0.68)
Jul 24, 2025	2025 (Q2)	4.17 / 4.35	3.94	10.41% (+0.41)
Apr 29, 2025	2025 (Q1)	3.74 / 3.84	3.68	4.35% (+0.16)
Feb 06, 2025	2024 (Q4)	3.39 / 3.45	3.3	4.55% (+0.15)
Oct 24, 2024	2024 (Q3)	3.47 / 3.50	3.38	3.55% (+0.12)
Aug 01, 2024	2024 (Q2)	3.78 / 3.94	3.42	15.20% (+0.52)
Apr 25, 2024	2024 (Q1)	3.48 / 3.68	3.282	12.13% (+0.40)
Feb 15, 2024	2023 (Q4)	3.26 / 3.30	3.557	-7.23% (-0.26)
Oct 26, 2023	2023 (Q3)	3.33 / 3.38	4.02	-15.92% (-0.64)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 28, 2025	$275.66	$259.69	-5.79%
Jul 24, 2025	$249.86	$267.00	+6.86%
Apr 29, 2025	$228.34	$239.10	+4.71%
Feb 06, 2025	$247.91	$245.68	-0.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Labcorp Holdings Inc. (LH) report earnings?

Labcorp Holdings Inc. (LH) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).

What is Labcorp Holdings Inc. (LH) earnings time?

Labcorp Holdings Inc. (LH) earnings time is at Feb 05, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LH EPS forecast?

LH EPS forecast for the fiscal quarter 2025 (Q4) is 3.94.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing